Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Revenue (2017 - 2025)

Autolus Therapeutics' Revenue history spans 6 years, with the latest figure at $24.3 million for Q4 2025.

  • For Q4 2025, Revenue rose 83655.17% year-over-year to $24.3 million; the TTM value through Dec 2025 reached $75.4 million, up 644.28%, while the annual FY2025 figure was $75.4 million, 644.94% up from the prior year.
  • Revenue reached $24.3 million in Q4 2025 per AUTL's latest filing, up from $21.2 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $24.3 million in Q4 2025 to a low of $29000.0 in Q4 2024.
  • Average Revenue over 4 years is $9.7 million, with a median of $9.0 million recorded in 2025.
  • The largest YoY upside for Revenue was 83655.17% in 2025 against a maximum downside of 11.07% in 2025.
  • A 4-year view of Revenue shows it stood at $166000.0 in 2022, then skyrocketed by 144.58% to $406000.0 in 2023, then tumbled by 92.86% to $29000.0 in 2024, then surged by 83655.17% to $24.3 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Revenue are $24.3 million (Q4 2025), $21.2 million (Q3 2025), and $20.9 million (Q2 2025).